| Family: | Invesco |
| Name: | Invesco Nasdaq Biotechnology ETF |
| Inception Date: | 11-Jun-2021 |
| Termination Date: | |
| Investment Objective: | The Invesco Nasdaq Biotechnology ETF (Fund) is based on the Nasdaq Biotechnology Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The Fund and the Index are reconstituted annually in December and rebalanced quarterly in March, June, September and December. |
| Prospectus | |
| Top 10 Holdings | ||
| GILEAD SCIENCES INC USD 0.001 | GILD | 9.6169% |
| VERTEX PHARMACEUTICALS INC USD 0.01 | VRTX | 9.3072% |
| AMGEN INC USD 0.0001 | AMGN | 9.1271% |
| REGENERON PHARMACEUTICALS USD 0.001 | REGN | 6.0306% |
| ALNYLAM PHARMACEUTICALS IN USD 0.01 | ALNY | 3.2859% |
| INSMED INC USD 0.01 | INSM | 2.3805% |
| BIOGEN INC | BIIB | 2.1024% |
| ARGENX SE EUR 0.1 ADR | ARGX | 1.6700% |
| UNITED THERAPEUTICS CORP D USD 0.01 | UTHR | 1.6225% |
| MODERNA INC USD 0.0001 | MRNA | 1.5649% |
| Top 10 Holdings Weight: | 46.7% |
| Number of Holdings: | 263 |
| Shares Outstanding: | 2,520,001 |
| Total Net Assets: | 75,675,630 |
| NAV: | 30.06 |
| Net Expense Ratio: | 0.19% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
